Released: January 31, 2024
Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Lung Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2024 (FY24)
The FY24 Defense Appropriations Bill has not been signed into law. Although FY24 funds have not been appropriated for the Lung Cancer Research Program (LCRP), the LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government.
The FY24 Defense Appropriations Act provides funding for the LCRP to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).
The LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY24 LCRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.
Applications submitted to the FY24 LCRP must address one or more of the following Areas of Emphasis:
- Biology and Etiology
- Understand the molecular mechanisms of initiation and progression to lung cancer.
- Understand contributors to lung cancer development other than tobacco.
- Understand the biology of metastatic/oligometastatic disease progression.
- Identify innovative strategies for prevention of the occurrence of lung cancer(s) or subsequent primaries.
- Identify innovative strategies for the prevention of recurrence or metastases from lung cancer.
- Detection, Diagnosis, and Surveillance
- Improve and expand approaches to screening and early detection of lung cancer.
- Identify strategies for prompt detection and/or characterization of progressive disease.
- Treatment and Prognosis
- Identify innovative strategies for the treatment of lung cancer, including overcoming resistance.
- Develop or optimize biomarkers to assist with therapeutic decision-making.
- Enhance the understanding, detection, and treatment of brain and leptomeningeal metastases in lung cancer.
- Health Outcomes and Survivorship
- Identify and understand the long-term and cumulative effects of lung cancer and its treatment(s) on patients, families, and support systems with respect to the impact on quality of life including, but not limited to, physiological, psychosocial, cognitive, and financial effects.
- Identify and understand impact of comorbidities on survivorship care in all stages of lung cancer.
- Advance equity and reduce lung cancer disparities among underserved and underrepresented populations.
Relevance to Military Health: The LCRP seeks to support research that is relevant to the healthcare needs of military Service Members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the Defense Health Program and FY24 LCRP during programmatic review. Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:
- Use of military of Veteran populations, biospecimens, data/databases, or programs in the proposed research
- Collaboration with DOD or Department of Veterans Affairs investigators
- Explanation of how the project addresses an aspect of lung cancer that has a direct relevance or is unique to the military, Veterans, other military health system beneficiaries, or Family readiness of Service Members, including environmental exposures other than tobacco
|Key Mechanism Elements
|Investigators at all academic levels
|Career Development Award
Principal Investigator: Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment
Mentor: At or above the level of Associate Professor (or equivalent); have a proven publication and funding record in lung cancer research
|Idea Development Award
Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent)
New Investigators: Investigators that meet the following criteria by the application submission deadline date:
|Translational Research Award
|Investigators at or above the level of Assistant Professor (or equivalent)
|Independent investigators at or above the level of Assistant Professor
A pre-application is required and must be submitted through the Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Thursday, February 8, 2024